Your browser is no longer supported. Please, upgrade your browser.
Settings
SNGX Soligenix, Inc. daily Stock Chart
SNGX [NASD]
Soligenix, Inc.
Index- P/E- EPS (ttm)-0.71 Insider Own3.54% Shs Outstand23.41M Perf Week0.91%
Market Cap61.09M Forward P/E- EPS next Y-0.14 Insider Trans0.00% Shs Float19.33M Perf Month10.45%
Income-15.30M PEG- EPS next Q-0.13 Inst Own12.70% Short Float1.78% Perf Quarter45.10%
Sales4.40M P/S13.89 EPS this Y28.50% Inst Trans-35.68% Short Ratio0.25 Perf Half Y-18.68%
Book/sh0.15 P/B14.80 EPS next Y76.30% ROA-174.10% Target Price- Perf Year80.49%
Cash/sh0.26 P/C8.49 EPS next 5Y1.00% ROE-542.20% 52W Range0.85 - 3.54 Perf YTD53.10%
Dividend- P/FCF- EPS past 5Y31.70% ROI-662.00% 52W High-37.71% Beta1.38
Dividend %- Quick Ratio1.50 Sales past 5Y-8.00% Gross Margin21.30% 52W Low159.41% ATR0.25
Employees15 Current Ratio1.50 Sales Q/Q-18.20% Oper. Margin- RSI (14)50.45 Volatility11.57% 10.16%
OptionableNo Debt/Eq0.00 EPS Q/Q-257.20% Profit Margin- Rel Volume0.49 Prev Close2.22
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume1.37M Price2.20
Recom2.00 SMA200.82% SMA506.90% SMA20022.62% Volume394,418 Change-0.68%
Jul-28-20Downgrade Dawson James Buy → Neutral
Jan-31-18Downgrade H.C. Wainwright Buy → Neutral $5.50 → $2.70
Aug-14-17Reiterated Maxim Group Buy $4 → $5
Jul-17-17Initiated H.C. Wainwright Buy $11
Jul-28-20 07:00AM  
Jul-20-20 07:00AM  
Jun-30-20 07:00AM  
Jun-26-20 02:53PM  
06:32AM  
Jun-24-20 07:00AM  
Jun-22-20 07:00AM  
05:39AM  
Jun-09-20 07:00AM  
May-28-20 03:28PM  
May-20-20 07:07AM  
May-17-20 10:59AM  
May-15-20 07:00AM  
May-11-20 07:00AM  
May-07-20 07:00AM  
May-05-20 05:40AM  
Apr-30-20 07:00AM  
Apr-16-20 08:09AM  
07:00AM  
Apr-06-20 07:00AM  
Apr-01-20 10:53AM  
Mar-31-20 10:25AM  
Mar-30-20 07:00AM  
Mar-24-20 09:11AM  
Mar-23-20 07:00AM  
05:45AM  
Mar-20-20 08:37AM  
Mar-19-20 06:00AM  
Feb-27-20 07:00AM  
Feb-20-20 08:49AM  
Feb-18-20 06:05AM  
Feb-13-20 08:05AM  
07:00AM  
Feb-11-20 07:00AM  
Feb-03-20 07:00AM  
Jan-30-20 08:12AM  
07:00AM  
Jan-28-20 02:38PM  
Jan-16-20 08:42AM  
Jan-06-20 04:40AM  
Dec-20-19 10:52AM  
Dec-18-19 07:00AM  
Dec-13-19 04:00PM  
Dec-12-19 07:00AM  
Dec-11-19 01:30PM  
Dec-05-19 05:35AM  
Dec-03-19 07:00AM  
Nov-18-19 07:00AM  
Nov-14-19 10:11AM  
09:40AM  
Nov-12-19 07:00AM  
Nov-06-19 07:00AM  
Oct-24-19 07:00AM  
Oct-22-19 08:48AM  
Oct-03-19 08:16AM  
07:00AM  
Sep-16-19 07:00AM  
Sep-11-19 07:00AM  
Aug-29-19 07:00AM  
Aug-28-19 11:30AM  
07:31AM  
07:30AM  
07:00AM  
Aug-22-19 11:30AM  
Aug-15-19 07:55AM  
07:00AM  
Aug-13-19 07:00AM  
Aug-01-19 10:20AM  
Jul-31-19 07:00AM  
Jul-29-19 09:10AM  
07:00AM  
Jul-15-19 09:00AM  
Jul-09-19 09:40AM  
Jul-08-19 07:00AM  
Jun-13-19 07:00AM  
May-28-19 07:00AM  
May-22-19 10:00AM  
May-14-19 07:00AM  
Apr-23-19 10:20AM  
07:00AM  
Apr-18-19 07:00AM  
Apr-15-19 07:00AM  
Apr-09-19 07:00AM  
Apr-04-19 07:00AM  
Mar-29-19 02:15PM  
Mar-26-19 07:00AM  
Mar-11-19 07:00AM  
Feb-12-19 11:15AM  
Feb-11-19 07:00AM  
Feb-07-19 07:00AM  
Jan-23-19 06:00AM  
Dec-11-18 08:22AM  
06:00AM  
Dec-05-18 06:00AM  
Nov-19-18 11:45AM  
Nov-14-18 08:55AM  
Nov-12-18 06:00AM  
Nov-09-18 06:00AM  
Oct-16-18 01:45PM  
Oct-15-18 01:15PM  
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301, a novel photodynamic therapy, which has completed Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology that is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal disorders characterized by severe inflammation, including pediatric Crohn's disease and acute radiation enteritis. The Public Health Solutions segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials; SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of antibiotic resistant and emerging infectious diseases; and ThermoVax, a technology in pre-clinical development for thermostabilizing vaccines. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
ZELDIS JEROME BDirectorNov 19Buy0.932,0001,85022,917Nov 19 04:19 PM
SCHABER CHRISTOPHER JChairman, CEO and PresidentNov 19Buy0.9310,77010,01653,095Nov 19 04:18 PM
Parks Diane L.DirectorSep 23Buy0.9314,94013,87014,940Sep 23 07:15 PM
ZELDIS JEROME BDirectorSep 19Buy0.944,0003,74020,917Sep 23 04:19 PM